11,363 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Acquired by Highland Capital Management LLC

Highland Capital Management LLC purchased a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 11,363 shares of the biotechnology company’s stock, valued at approximately $227,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ADMA. D. E. Shaw & Co. Inc. raised its stake in ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after acquiring an additional 1,442,799 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in ADMA Biologics by 2.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after acquiring an additional 92,281 shares in the last quarter. Driehaus Capital Management LLC raised its stake in ADMA Biologics by 17.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock worth $33,860,000 after acquiring an additional 447,743 shares in the last quarter. Mesirow Institutional Investment Management Inc. acquired a new stake in ADMA Biologics during the 1st quarter worth $17,221,000. Finally, Renaissance Technologies LLC raised its stake in ADMA Biologics by 28.7% during the 2nd quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock worth $28,868,000 after acquiring an additional 575,100 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on ADMA. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of ADMA Biologics in a research note on Monday, October 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $15.50.

Insider Transactions at ADMA Biologics

In other news, Director Young Kwon sold 60,000 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares in the company, valued at $4,408,712.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Young Kwon sold 60,000 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the transaction, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 466,900 shares of company stock worth $8,224,121 over the last ninety days. 3.70% of the stock is currently owned by company insiders.

ADMA Biologics Trading Down 0.9 %

NASDAQ ADMA opened at $15.81 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The firm has a market cap of $3.66 billion, a PE ratio of -790.50 and a beta of 0.62. ADMA Biologics, Inc. has a one year low of $3.16 and a one year high of $21.13. The firm’s fifty day moving average is $17.93 and its two-hundred day moving average is $13.03.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The company had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. ADMA Biologics’s quarterly revenue was up 78.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.02) earnings per share. Analysts expect that ADMA Biologics, Inc. will post 0.49 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.